title: Risperidone irreversibly binds to and inactivates the h5-HT7 serotonin receptor.
abstract: Risperidone displays a novel mechanism of antagonism of the h5-HT7 receptor. Pretreatment of the cells with 5 or 20 nM risperidone, followed by removal of the drug from the media, renders the 5-HT7 receptors unresponsive to 10 microM 5-HT for at least 24 h. Thus, risperidone seems to be producing a rapid, long-lasting inactivation of the h5-HT7 receptor. Whole-cell radioligand binding studies indicate that risperidone interacts in an irreversible or pseudo-irreversible manner with the h5-HT7 receptor, thus producing the inactivation. Internalization of the h5-HT7 receptor was not detected by monitoring green fluorescent protein-labeled fluorescent forms of the h5-HT7 receptor exposed to 20 nM risperidone. Ten other antagonists were tested for h5-HT7-inactivating properties, and only 9-OH-risperidone and methiothepin were found to demonstrate the same anomalous properties as risperidone. These results indicate that the h5-HT7 receptor may possess unique structural features that allow certain drugs to induce a conformation resulting in an irreversible interaction in the intact membrane environment. This may indicate that the h5-HT7 receptor is part of a subfamily of G-protein-coupled receptors (GPCRs) possessing this property or that many GPCRs have the potential to be irreversibly blocked, but only select drugs can induce this effect. At the very least, the possibility that highly prescribed drugs, such as risperidone, are irreversibly antagonizing GPCR function in vivo is noteworthy.
authors.affiliation: A-136, Center for Neuropharmacology and Neuroscience, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208, USA.
authors.forename: Carol
authors.initials: C
authors.lastname: Smith
authors.forename: Tariq
authors.initials: T
authors.lastname: Rahman
authors.forename: Nicole
authors.initials: N
authors.lastname: Toohey
authors.forename: Joseph
authors.initials: J
authors.lastname: Mazurkiewicz
authors.forename: Katharine
authors.initials: K
authors.lastname: Herrick-Davis
authors.forename: Milt
authors.initials: M
authors.lastname: Teitler
mesh_terms: D001667:Binding, Competitive; D002460:Cell Line; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D006801:Humans; D011485:Protein Binding; D043562:Receptors, G-Protein-Coupled / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism*; D018967:Risperidone / Q000737:chemistry / Q000493:pharmacokinetics*; D012702:Serotonin Antagonists / Q000737:chemistry / Q000493:pharmacokinetics; D013379:Substrate Specificity; D013997:Time Factors; D014162:Transfection
chemical_list: D043562:Receptors, G-Protein-Coupled; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C104425:serotonin 7 receptor; D018967:Risperidone